We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various unive... Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology. Show more
Completion of the additional equity investment of $140M by AstraZeneca, as previously announced on November 1 and 15, 2023 NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth:...
NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Cellectis (the โCompanyโ) (Euronext Growth: ALCLS โ NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
โขย ย Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American Society of Hematology (ASH) 65th Annual Meeting โขย ย Execution of strategic...
This novel editing approach might unlock new strategies for the treatment of metabolic and neurological diseasesNon-viral circular ssDNA delivery associated to TALENยฎ gene editing allows high...
NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the โCompanyโ) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform...
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Cellectis (the โCompanyโ) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.005 | -0.166112956811 | 3.01 | 3.32 | 2.95 | 65458 | 3.12415404 | CS |
4 | 0.475 | 18.7747035573 | 2.53 | 3.38 | 2.3 | 85059 | 2.98181933 | CS |
12 | 0.175 | 6.18374558304 | 2.83 | 3.38 | 2.3 | 53530 | 2.81531331 | CS |
26 | 0.265 | 9.67153284672 | 2.74 | 3.7735 | 2.3 | 83627 | 2.9539924 | CS |
52 | 1.305 | 76.7647058824 | 1.7 | 3.7735 | 0.962777 | 518346 | 2.70777509 | CS |
156 | -12.455 | -80.5627425614 | 15.46 | 16.86 | 0.962777 | 285312 | 4.40324066 | CS |
260 | -16.075 | -84.250524109 | 19.08 | 34.71 | 0.962777 | 254839 | 9.54734551 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions